精彩内容近日,上海医药的中药1.1类新药七味防己黄芪颗粒、悦康药业的中药1.2类新药百蕊提取物颗粒等申报IND获受理。米内网数据显示,2025上半年中国三大终端六大市场中成药颗粒剂/散剂销售额约300亿元;公立医疗机构品牌TOP20中,19个独家品种(含剂型独家,下同)上榜,步长制药的稳心颗粒稳居第一,国药、康臣、扬子江等亮眼;零售药店品牌TOP20中,华润医药的感冒灵颗粒强势领跑,广药、健民、...
Source Link精彩内容近日,上海医药的中药1.1类新药七味防己黄芪颗粒、悦康药业的中药1.2类新药百蕊提取物颗粒等申报IND获受理。米内网数据显示,2025上半年中国三大终端六大市场中成药颗粒剂/散剂销售额约300亿元;公立医疗机构品牌TOP20中,19个独家品种(含剂型独家,下同)上榜,步长制药的稳心颗粒稳居第一,国药、康臣、扬子江等亮眼;零售药店品牌TOP20中,华润医药的感冒灵颗粒强势领跑,广药、健民、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.